ZBIO
Zenas BioPharma, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.36B
P/E Ratio
—
EPS
$-8.44
Beta
—
52W High
$44.60
52W Low
$8.51
50-Day MA
$23.31
200-Day MA
$23.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $10.00M |
| Gross Profit (TTM) | $10.00M |
| EBITDA | $-211.33M |
| Operating Margin | -2114.00% |
| Return on Equity | -136.20% |
| Return on Assets | -35.10% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $4.44 |
| Price-to-Book | 5.59 |
| Price-to-Sales (TTM) | 135.70 |
| EV/Revenue | 101.29 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $62.36M |
| Float | $35.23M |
| % Insiders | 24.52% |
| % Institutions | 70.65% |
Historical Volatility
HV 10-Day
61.94%
HV 20-Day
96.85%
HV 30-Day
80.87%
HV 60-Day
78.63%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($42.00 target)
7
Buy1
HoldData last updated: 4/17/2026